Weekly Recap: Brenetafusp safety data at SITC and Buy rating, $100 target

What happened

Immunocore is set to present new safety and efficacy data for brenetafusp, alone and with KIMMTRAK, in metastatic uveal melanoma at the SITC meeting on November 6–7, 2026. HC Wainwright reiterated its Buy rating and $100 price target for the company’s shares.

Confirmed

Global impact / market context

The presentation may give investors evidence about brenetafusp’s safety and potential effectiveness, which could shape expectations for Immunocore’s treatment prospects. The reiterated Buy rating and target reflect one research firm’s view, but neither confirms clinical success nor guarantees the shares will reach that price.

Analyst inference

The article reports upcoming clinical data and an analyst rating, not trial results or a company financial update. For investors, the key distinction is that safety and efficacy findings could inform future expectations, while the $100 target is an opinion rather than an observed market price.

Analyst inference

What to watch

1. At the November 6–7, 2026 SITC meeting, look for the announced brenetafusp safety and efficacy data in metastatic uveal melanoma, both alone and with KIMMTRAK. Confirmed
2. Assess whether the presented findings describe safety concerns and treatment effects clearly; the article gives no results, so the size or direction of any clinical signal is unknown. Analyst inference
3. Compare future company updates with HC Wainwright’s reiterated Buy rating and $100 target, recognizing that the article provides no rationale for the rating or evidence that the target will be reached. Analyst inference

Evidence

• Original source link unavailable